Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

 Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

Acceleron to Discontinue P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy

Shots:

  • The P-II clinical study involves assessing ACE-083 in FSHD patient with muscle weakness in the biceps brachii, the tibialis anterior, and a muscle in the lower leg involved in foot dorsiflexion in two parts. Part 1 study evaluates ACE-083 for 3mos. and PBO controlled Part 2 study evaluates it for 6mos. following 6mos. open-label treatment
  • The P-II clinical studies resulted in improving 1EPs i.e, increase in mean total muscle volume but the increment failed to improve functional tests
  • ACE-083 is a selective TGF-beta protein inhibitor that negatively regulates muscle growth with its expected results of P-II study for Charcot-Marie-Tooth disease in Q1’20

Click here to­ read full press release/ article | Ref: Acceleron Pharma | Image: Investor’s Business Daily

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post